The Costs of Biopharmaceutical Firms Going Public in the U.S.

David Williams

Abstract


The purpose of this paper is to examine the process and costs associated with biopharmaceutical firms undertaking an initial public offering. It discusses the direct and opportunity costs associated with this process. It shows the historical mispricing of firms and costs associated with biopharmaceutical firms going public over the past several years. Private biopharmaceutical firms need to be aware of the process and costs of going public in order to determine if these costs are acceptable, compare these costs (and benefits) with those of other sources of funding, and better manage the IPO process.


Full Text:

PDF

References


Williams, DR Human and financial capital as determinants of biopharmaceutical IPO de-listings. J. Bus. Res. 2013; 66: 2612-2618.

Former, JD Should your small business go public? Consider the benefits and risks of becoming a publicly traded company. http://www.sba.gov/community/blogs/community-blogs/business-law-advisor/should-your-small-business-go-public-consider-0. Accessed June 15, 2014.

Rockoff, JD, Demos, T How biotechs got hot: Sizzling IPO market reflects upswing in drug approvals amid R&D success. Wall Street Journal. July 1, 2013.

Hoovers, IPO Central. http://www.hoovers.com/ipo-central/ipo-performance/100004163-1.html. Accessed July 5, 2013.

Giovnnetti, G. 2015. 2014: A new benchmark year for biotech IPOs. http://lifesciencesblog. ey.com/ 2015/01/09/2014-a-new-benchmark-year-for-biotech-ipos-infographic/. Accessed March 18, 2015.

Shimasaki, CD What makes a biotech entrepreneur? In The business of bioscience: what goes into making a biotechnology product. Springer Science+Business Media, LLC. 2009.

Price Waterhouse Coopers Considering an IPO? The costs of going and being public may surprise you. http://www.pwc.com/en_us/us/ transaction-services/publications/assets/pwc-cost-of-ipo.pdf. Accessed February 15, 2013.

Gable, GG A multidimensional model of client success when engaging external consultants. Man. Sc. 1996; 42(8): 1175.

Gable, J Eight tips for working with a consultant. The Inform. Man. J. 2007; July/August: 42-48.

Ritter, J Initial public offerings. Contempt. Fin. Dig. 1998; 2(1): 5-30.

Golec, J Vernon, J New estimates of pharmaceutical research and development spending by US-based firms from 1984 to 2003. Manag. Decis. Econ. 2007; 28: 4881-3.

Henderson, J The role of corporate venture capital funds in financing biotechnology and healthcare: differing approaches and performance consequences. Int. J. Technoentre, 2009; 2(1): 29-44.

WilmerHale 2009 IPO report. ttp://www.wilmerhale.com/uploadedFiles/WilmerHale_Shared_ Content/Files/Editorial/Publication/2009_IPO_Report.pdf. Accessed January 15, 2014.

Holaday, J Meltzer, S McCormick, J Strategies for attracting angel investors. J. Com. Biotech. 2003; 9 (2): 129-133.

Williams DR, Young, CC The role of pre-IPO financial indicators and intermediaries in aftermarket performance and survival in the US biopharmaceutical market. 2012: J Pharm. Innov. 7: 127-139.

Chang C, Chiang YM, Qian Y, Ritter JR Pre-market trading and IPO pricing (June 3, 2014). Available at SSRN: http://ssrn.com/abstract=2402806 or http://dx.doi.org/10.2139/ ssrn.2402806. Accessed June 15, 2014.

Kortum S, Lerner J Assessing the contribution of venture capital to innovation. Rand J. Econ. 2000; 31(4): 674-692.

Lerner J, Merges R The control of technology alliances: An empirical analysis of the biotechnology industry. J Indus. Econ. 1998; 46(2): 125-156.

Brander JA, Amit R, Antweiler W Venture-capital syndication: improved venture selection vs.the value-added hypothesis. J. Econ. & Man. Strat. 2002; 11(3): 423–452.

Benveniste LM, Busaba WY Bookbuilding vs. fixed price: an analysis of competing strategies for marketing IPOs. J. Fin. Quant. Anal. 1997; 32(4): 383-403.

Loughran T, Ritter J Why don’t issuers get upset about leaving money on the table in IPOs? Rev. Financ. Stud. Spec. 2002; 15(2), 413-443.

Certo ST, Daily CM, Dalton DR Signaling firm value through board structure: an investigation of initial public offerings. Entrep. Theor. & Pract. 2001; 26(2): 33-51.

Loughran T, Ritter J Why has IPO underpricing changed over time? Fin. Man. 2004: Autumn; 5-37.

Solomon SD Why IPOs get underpriced. New York Times. 2011. http://dealbook. nytimes.com/ 2011/05/27/why-i-p-o-s-get-underpriced/. Accessed July 8, 2014.

Ritter J Money left on the table in IPOs by firm. http://bear.warrington.ufl.edu/ritter/ work_papers/monew.pdf. Accessed February 20, 2013.


Refbacks

  • There are currently no refbacks.


©Journal of Health Care Finance